Imaging metal homeostasis in the ageing brain. This fellowship aims to deliver new tools to visualise how changes to blood vessels during ageing effect the amount and distribution of metal ions in brain cells in animal models. This will be a significant advance as current methods cannot image these parameters. Metal ions are essential for brain function, but the effects of ageing on metal ions within brain cells is largely unknown. The results are expected to associate brain-blood vessel permeab ....Imaging metal homeostasis in the ageing brain. This fellowship aims to deliver new tools to visualise how changes to blood vessels during ageing effect the amount and distribution of metal ions in brain cells in animal models. This will be a significant advance as current methods cannot image these parameters. Metal ions are essential for brain function, but the effects of ageing on metal ions within brain cells is largely unknown. The results are expected to associate brain-blood vessel permeability with changes to metal ion content during ageing. The methods developed, and the fundamental new knowledge they reveal will benefit national and international neuroscientists seeking to elucidate the fundamental neurobiology of metal ions with respect to maintaining healthy brain function.Read moreRead less
Accessing the therapeutic potential of carbon monoxide. Despite carbon monoxide being regarded as the ”silent killer”, it is now established that this molecule has beneficial effects for a number of conditions and pathologies, including inflammation, organ transplant rejection, bacterial infection, acute liver failure and as an aid in cancer therapies. This project proposes to explore the photochemistry of rhenium-containing species to discover more efficient carbon monoxide delivery agents. By ....Accessing the therapeutic potential of carbon monoxide. Despite carbon monoxide being regarded as the ”silent killer”, it is now established that this molecule has beneficial effects for a number of conditions and pathologies, including inflammation, organ transplant rejection, bacterial infection, acute liver failure and as an aid in cancer therapies. This project proposes to explore the photochemistry of rhenium-containing species to discover more efficient carbon monoxide delivery agents. By combining synthetic chemistry, photochemistry and cellular biology it is anticipated that this multidisciplinary research programme will advance the area of carbon monoxide therapies by preparing safer agents for the targeted and controlled delivery of carbon monoxide.Read moreRead less
NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these ne ....NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.Read moreRead less
DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the dr ....DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100174
Funder
Australian Research Council
Funding Amount
$800,000.00
Summary
Innovative synchrotron science - program for access to the Australian National Beamline Facility and cutting-edge beamlines at international synchrotrons. Synchrotron science dramatically affects the community through the innovative scientific, engineering and medical research outcomes it produces. This program for access to synchrotron beamlines is aimed at enhancing Australia's high international standing in synchrotron science and will have many flow-on effects in areas such as health and ind ....Innovative synchrotron science - program for access to the Australian National Beamline Facility and cutting-edge beamlines at international synchrotrons. Synchrotron science dramatically affects the community through the innovative scientific, engineering and medical research outcomes it produces. This program for access to synchrotron beamlines is aimed at enhancing Australia's high international standing in synchrotron science and will have many flow-on effects in areas such as health and industry.Read moreRead less
Targeting mitochondrial dysfunction in disease. Defects in mitochondria, the energy producing compartments within cells, lead to severe neurodegenerative diseases and contribute to the development of cancer. Treatment for such diseases caused by mutations in mitochondrial DNA remains unsatisfactory and mostly confined to supportive measures. The identification of proteins that regulate gene expression within mitochondria provides an unexplored resource of potential disease modulators and drug ta ....Targeting mitochondrial dysfunction in disease. Defects in mitochondria, the energy producing compartments within cells, lead to severe neurodegenerative diseases and contribute to the development of cancer. Treatment for such diseases caused by mutations in mitochondrial DNA remains unsatisfactory and mostly confined to supportive measures. The identification of proteins that regulate gene expression within mitochondria provides an unexplored resource of potential disease modulators and drug targets. This research will lead to new strategies in the design of improved anticancer drugs, which is an important Australian research priority that will promote and maintain good health, and provide potential commercial outcomes.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
Gold-based mitochondria targeted chemotherapeutics: mechanistic studies probing interactions with thiol and selenol containing proteins. Cancer affects one in four Australians and prostate cancer is the most commonly diagnosed and second leading cause of male cancer deaths, for which there is currently no effective treatment. Current chemotherapeutics must overcome drug resistance and lack of selectivity between tumour and normal cells. To circumvent these problems we are investigating gold-base ....Gold-based mitochondria targeted chemotherapeutics: mechanistic studies probing interactions with thiol and selenol containing proteins. Cancer affects one in four Australians and prostate cancer is the most commonly diagnosed and second leading cause of male cancer deaths, for which there is currently no effective treatment. Current chemotherapeutics must overcome drug resistance and lack of selectivity between tumour and normal cells. To circumvent these problems we are investigating gold-based compounds, which act by a novel mechanism. The research will lead to new strategies in the design of improved anticancer drugs, an important Australian research priority that will promote and maintain good health. Other benefits arise from training PhD students with interdisciplinary skills for Australian biotechnology industries.Read moreRead less
In situ Raman spectroscopic studies of iron and calcium biomaterials in marine chiton teeth. The future of biomaterial science in Australia depends upon the discovery and refinement of new materials. This project characterizes the biomaterials in the feeding apparatus of Australian marine chitons (Mollusca: Polyplacophora). Like many biological structures, chiton teeth are sophisticated composite materials that have been refined by evolution over millions of years. Initially composed of the poly ....In situ Raman spectroscopic studies of iron and calcium biomaterials in marine chiton teeth. The future of biomaterial science in Australia depends upon the discovery and refinement of new materials. This project characterizes the biomaterials in the feeding apparatus of Australian marine chitons (Mollusca: Polyplacophora). Like many biological structures, chiton teeth are sophisticated composite materials that have been refined by evolution over millions of years. Initially composed of the polysaccharide chitin, these extremely hard teeth are mineralized with calcium and iron compounds and used to excavate the rocks on which they live, as they graze for food. Understanding the mechanism of biomineralization is vital for devising synthetic routes to composite materials for industrial purposes.Read moreRead less
Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration betwe ....Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less